These findings bring to light the potential of mGlu7 negative allosteric modulators as promising candidates for pharmacological disruption of fear memory reconsolidation, which may ultimately translate into treatments in human subjects for PTSD and phobia. Here, GRM7 is linked to phobic disorder.